Drug intelligence / Profile preview

MG-D-1001

Development stage: Unknown
Lead developer: Metagone Biotech
Modality: Small Molecules
Administration: Ophthalmic

Overview

MG-D-1001 is a small molecule Rho-associated protein kinase (ROCK) inhibitor being developed by Metagone Biotech for the treatment of glaucoma. ROCK inhibitors represent a therapeutic class that lowers intraocular pressure (IOP) by increasing the outflow of aqueous humor through the trabecular meshwork, rather than reducing fluid production. By targeting the Rho/ROCK pathway, MG-D-1001 promotes the relaxation of the trabecular meshwork and the inner wall of Schlemm's canal, facilitating drainage. The drug is currently in Phase 2 clinical development.

Targets

ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on MG-D-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG-D-1001.

Explore the full profile